# Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

> **NCT02599454** · PHASE1 · COMPLETED · sponsor: **Megan Daly, MD** · enrollment: 20 (actual)

## Conditions studied

- Stage I Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT02599454
- **Lead sponsor:** Megan Daly, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2019-12-27
- **Final completion:** 2024-02-20
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02599454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02599454, "Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02599454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*